
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
Details : eRapa, a proprietary encapsulated form of rapamycin, also known as sirolimus, is being developed for the treatment of familial adenomatous polyposis (FAP).
Product Name : eRapa
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 12, 2025
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : Emtora Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Details : ERapa (Rapamycin) is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Adenomatous Polyposis Coli.
Product Name : eRapa
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 30, 2025
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : Emtora Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa Succeeds in FDA Type C Meeting for eRapa Phase 3 in FAP
Details : eRapa, a proprietary encapsulated form of rapamycin, also known as sirolimus, is being developed for the treatment of familial adenomatous polyposis (FAP).
Product Name : eRapa
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa's FAP Drug Gains FDA Fast Track After Positive Phase 2 Results
Details : eRapa, a proprietary encapsulated form of rapamycin, also known as sirolimus, is being developed for the treatment of familial adenomatous polyposis (FAP).
Product Name : eRapa
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 12, 2025
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Details : eRapa, a proprietary encapsulated form of rapamycin, also known as sirolimus, is being developed for the treatment of familial adenomatous polyposis (FAP).
Product Name : eRapa
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa’s MX-110 Promising in Recurrent Glioblastoma Treatment
Details : MTX110 is a proprietary combination of water-soluble panobinostat. It is being evaluating in the early-stage trial studies for the treatment of recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2024
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa Provides Update On Progression Free and Overall Survival in MTX110 Study
Details : MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat, which is being evaluated for the treatment of recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2024
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : CPRIT
Deal Size : $17.0 million
Deal Type : Funding
Company Pays $3M Final Match For $17M CPRIT Grant Access
Details : The proceeds will be used to fund company's upcoming Phase 3 registrational study of eRapa, a proprietary oral tablet formulation of rapamycin, in Familial Adenomatous Polyposis.
Product Name : eRapa
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : CPRIT
Deal Size : $17.0 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Ladenburg Thalmann & Co
Deal Size : $5.0 million
Deal Type : Public Offering
Announces Pricing of $5M Registered Direct Offering and Concurrent Private Placement
Details : The net proceeds will be used to advance the clinical development of eRapa (rapamycin), also known as sirolimus. It is being evaluated for treating Familial Adenomatous Polyposis.
Product Name : eRapa
Product Type : Antibiotic
Upfront Cash : Undisclosed
July 19, 2024
Lead Product(s) : Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Ladenburg Thalmann & Co
Deal Size : $5.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biodexa Announces Health Canada Approval for Phase 2a Tolimidone in Type 1 Diabetes
Details : MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase which increases phosphorylation of insulin substrate 1, being developed for the treatment of type 1 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 16, 2024
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
